9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma

Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma

Estimated reading time: < 1 min

Condition: Carcinoma, Non-Small-Cell Lung

Estimated Enrollment: 18

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: Pharmacokinetic (PK) parameters,  Response rate assessed by comparing tumor size via radiology scans (CTs or MRIs),  Safety (until disease progression, unacceptable toxicity or study completion) assessed by duration of patient participation, Tolerability (until disease progression, unacceptable toxicity or study completion) assessed by duration of patient participation

Interventions: LBH589,

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: January 2009

Completion Date:

Last  Posted Date: November 27, 2012

Location: Highlands Oncology Group, Fayetteville, Arkansas, United States

Website Link: https://ClinicalTrials.gov/show/NCT00535951

Was this article helpful?
Dislike 0